Abstract
Ross Levine is a physician-scientist at Memorial Sloan Kettering Cancer Center in New York, where his laboratory studies the genetic basis of myeloid malignancies. Work from Ross' laboratory has shown how mutations in the JAK-STAT pathway and epigenetic regulators play a role in myeloproliferative neoplasms, and JAK inhibitors are now successfully used to treat myeloproliferative neoplasms. We spoke to Ross about his journey in science so far.